Skip to main content
Veterinary Medicines

Milbenin 2.5 mg/25 mg chewable tablets for small dogs and puppies

Authorised
  • Milbemycin oxime
  • Praziquantel

Product identification

Medicine name:
Milbenin 2.5 mg/25 mg chewable tablets for small dogs and puppies
Milbenin 2,5 mg/25 mg comprimidos mastigáveis para cães pequenos e cachorros
Active substance:
  • Milbemycin oxime
  • Praziquantel
Target species:
  • Dog (puppy)
  • Dog
Route of administration:
  • Oral use
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    2.50
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    25.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog (puppy)
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:
  • 2 or 4 tablets in OPA-Al-PVC/AL blisters. 12 blisters of 4 chewable tablets introduced in carton box.
  • 2 or 4 tablets in OPA-Al-PVC/AL blisters. 1 blister of 4 chewable tablets introduced in carton box.
  • 2 or 4 tablets in OPA-Al-PVC/AL blisters. 1 blister of 2 chewable tablets introduced in carton box.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Pharma VIM Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Vim Spectrum S.R.L.
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 1566/01/23DFVPT
Date of authorisation status change:
Reference member state:
  • Hungary
Procedure number:
  • HU/V/0146/001
Concerned member states:
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Luxembourg
  • Netherlands
  • Portugal
  • Romania
  • Spain

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 10/12/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."